Finding Value in Biotech

This small-cap biotech stock is severely undervalued.
Author:
Publish date:

Updated from 2:45 p.m. EDT, March 16

Cheap is a relative term for investors and traders.

Many thought

General Electric

(GE) - Get Report

was cheap at $20 but did not fully discount the negative effects of GE Capital on the broader company. Some thought

Potash

(POT)

was cheap at $120 but did not realize how a slowing world economy would adversely affect demand for its fertilizer.

Dry Ships

(DRYS) - Get Report

looked cheap to some investors at $15, but they failed to factor in the company's dependence on the credit markets as a source of funds.

A good way to screen for relatively cheap stocks is by comparing a company's net cash and market capitalization. If its net cash level is larger than its current market cap, the company warrants additional research.

One intriguing name here is

Cyclacel Pharmaceuticals

(CYCC) - Get Report

, which has a market capitalization of just $6.1 million, or 30 cents per share, with zero debt and net cash sitting in the bank of $33.7 million, which equates to $1.65 per share in cash.

To read more,

visit Stockpickr.com

.

Who's on Stockpickr Answers?

Eric Jackson

will be on

Stockpickr Answers

on March 16 to respond to investing and trading questions posed by members of the Stockpickr community. Not a member?

Join the Stockpickr community today -- free.

P.S. Where is Jim Cramer putting his own money? Take a free peek at his personal portfolio to see all his buys and sells by clicking here. When you do, Jim will also send you exclusive email alerts telling you everything he's about to add to or shed from his Action Alerts PLUS portfolio -- before he makes his trade.

Stockpickr is a wholly owned subsidiary of TheStreet.com.